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Abstract
Background: There is a lack of severity assessment tools to identify adults presenting with febrile urinary tract
infection (FUTI) at risk for complicated outcome and guide admission policy. We aimed to validate the Prediction
Rule for Admission policy in Complicated urinary Tract InfeCtion LEiden (PRACTICE), a modified form of the
pneumonia severity index, and to subsequentially assess its use in clinical practice.
Methods: A prospective observational multicenter study for model validation (2004–2009), followed by a multicenter
controlled clinical trial with stepped wedge cluster-randomization for impact assessment (2010–2014), with a follow up
of 3 months. Paricipants were 1157 consecutive patients with a presumptive diagnosis of acute febrile UTI (787 in
validation cohort and 370 in the randomized trial), enrolled at emergency departments of 7 hospitals and 35 primary
care centers in the Netherlands.
The clinical prediction rule contained 12 predictors of complicated course. In the randomized trial the PRACTICE
included guidance on hospitalization for high risk (>100 points) and home discharge for low risk patients (<75 points),
in the control period the standard policy regarding hospital admission was applied. Main outcomes were effectiveness
of the clinical prediction rule, as measured by primary hospital admission rate, and its safety, as measured by the rate of
low-risk patients who needed to be hospitalized for FUTI after initial home-based treatment, and 30-day mortality.
Results: A total of 370 patients were included in the randomized trial, 237 in the control period and 133 in the
intervention period. Use of PRACTICE significantly reduced the primary hospitalization rate (from 219/237, 92%, in the
control group to 96/133, 72%, in the intervention group, p < 0.01). The secondary hospital admission rate after initial
outpatient treatment was 6% in control patients and 27% in intervention patients (1/17 and 10/37; p < 0.001).
Conclusions: Although the proposed PRACTICE prediction rule is associated with a lower number of hospital
admissions of patients presenting to the ED with presumptive febrile urinary tract infection, futher improvement is
necessary to reduce the occurrence of secondary hospital admissions.
Trial registration: NTR4480 http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=4480, registered retrospectively
25 mrt 2014 (during enrollment of subjects).
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Background
The majority of adults presenting to hospital with an acute
febrile illness suffer from respiratory or urinary tract infec-
tions [1, 2]. The course of infection may be unpredictable
and fever may reflect the onset of sepsis with potential
progression to septic shock and multi organ failure. How-
ever, adults with fever of bacterial origin usually present
with a mild illness at emergency departments (ED) and re-
spond favourably to antibiotic treatment. It thus appears
that the vast majority of these patients can be managed
safely as outpatients. In daily clinical practice the need for
hospital-based treatment for febrile urinary tract infection
(FUTI) is assessed on basis of history, comorbidity and on
severity of local and vital signs.
For respiratory tract infection there are validated clinical
rules to calculate the mortality risk, such as the Pneumo-
nia Severity Index (PSI), which is used to provide guidance
on decisions regarding treatment and hospital admission
[3–5]. To date, there are no such rules to assess the risk of
poor outcome in patients presenting with FUTI.
The risk of complicated course of FUTI increases with
age and comorbidity, but the event rate of life-threatening
complications is low [6–8]. Physicians tend to apply low
thresholds for hospitalization, which suggests that many ad-
missions may be avoidable [9, 10]. Therefore, clinical tools
that predict prognosis in patients with FUTI are needed to
identify those who benefit from hospital admission, and
those who may safely be managed as outpatients.
The main predicting factors of mortality in the PSI are
not specific for pneumonia such as age, co-morbidity and
physical or laboratory signs of sepsis [3]. We therefore
considered that this risk assessment might also apply for
community-acquired infections other than pneumonia. As
our focus was on the evaluation of a practical and bedside
available prediction tool, we modified the PSI by erasing
all the laboratory variables (Table 1) and changed the
name in the Prediction Rule for Admission policy in Com-
plicated urinary Tract InfeCtion LEiden (PRACTICE). We
used data from a prospective observational multi-center
cohort study that included 787 consecutive adults with fe-
brile UTI between 2004 and 2009 to validate this PSI-
derived prediction rule for complicated course in patients
with FUTI (all details and methods are described in the
Additional file 1). In this validation cohort, the PRAC-
TICE score identified those at very low risk for 30-day
mortality and ICU admission; the area under the curve
(AUC) of the receiver operating characteristic curve for
these outcomes indicated a good discriminatory power
(AUC 30-day mortality: 0.91; AUC 30-day mortality or
ICU admission: 0.84). The PRACTICE score was devided
in 5 risk categories (see Additional file 1: Table S1), show-
ing that patients with a PRACTICE score < 100 points
(n = 636) had a very low risk (<2%) of adverse outcomes;
yet 380 (60%) of those were hospitalized. Using a cut-off
value of the PRACTICE score ≥ 100 resulted in a negative
predictive value for 30-day mortality of 1.00 and for the
composite endpoint ‘complicated course’ (30-day mortal-
ity, ICU admission or hospitalization >10 days) of 0.90.
Because the cut-off point was chosen to identify low-risk
patients, the positive predictive values (PPV) were low
(PVV 0.12 and 0.39, respectively). We assumed that the
PRACTICE is a good bedside clinical tool to distinguish
patients with FUTI at low risk of complicated course who
can be managed as outpatients.
The aim of the present study is to validate the PRAC-
TICE in a new prospective cohort to guide the need for
hospitalization in patients with FUTI presenting at EDs,




We performed a stepped wedge cluster-randomized trial
involving consecutive patients presenting with a presump-
tive diagnosis of FUTI, at the EDs of 7 hospitals in the
Netherlands, between January 2010 and June 2014 [11].
Table 1 Prediction Rule for Admission policy in Complicated
urinary Tract InfeCtion LEiden (PRACTICE)
Characteristic Allocated pointsa
Demographic
Age (men) Age (years)
Age (women) Age (years) - 10
Nursing home resident +10
Comorbidityb
Malignancy +30





Altered mental status +20
Respiratory rate ≥ 30/min +20
Systolic blood pressure < 90 mmHg +20
Pulse ≥125/min +10
Temperature ≥ 40 °C +15
aA total score individual patient score is obtained by summing the points for
each characteristic
bMalignancy is defined as any cancer except basal- or squamous-cell cancer of the
skin that was active within the previous year of presentation. Congestive heart
failure is defined as ventricular dysfunction for which the patient is prescribed
medication and/or consults a hospital-based medical specialist. Cerebrovascular
disease is defined as a history of stroke or transient ischemic attack. Liver disease is
defined as a clinical diagnosis of cirrhosis. Renal disease is defined as a history of
chronic renal disease
According to risk class the following recommendations will apply:
< 75 points strong recommendation towards home-based management
75–100 points consider home-based management
>100 points strong recommendation towards hospital admission
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These centers also participated in the validation cohort
study (see Additional file 1). All participating centers
started with a control period, in which routine clinical
practice with regard to hospitalization policy was applied.
The intervention (use of the PRACTICE) was introduced
at the participating centers sequentially, in random order.
By the end of the allocation all sites, except one, used the
PRACTICE to guide admission policy.
Inclusion criteria were age ≥ 18 years, fever (≥38.0 °C)
and/or a history of fever or shaking chills within 24 h
before presentation, at least one symptom of UTI (dys-
uria, perineal pain or flank pain) and a positive nitrite
dipstick test or leucocyturia. Exclusion criteria were
pregnancy, hemodialysis or peritoneal dialysis, a history
of kidney transplantation or polycystic kidney disease.
The study protocol was approved by the local Ethics
Committee, and all participants signed an informed con-
sent form prior to enrollment.
Intervention and treatment
The PRACTICE score ranges from 8 to >125. Based on
the validation cohort it was divided into three risk clas-
ses (low <75 points; intermediate 75–100 points; high
>100 points) with corresponding recommendations re-
garding hospitalization policy (Table 1). During the con-
trol period, the decision to treat the patient at home or
admission to hospital was made at the discretion of the
ED physician. At the start of the intervention period the
ED physicians were instructed to calculate the PRAC-
TICE score and on that basis decide on hospital-based
or home-based treatment. Preferably admission policy
was done according to the guidance as described in
Table 1, however, the attending physician was respon-
sible for the final decision on treatment location.
Throughout the whole study period the antibiotic ther-
apy was left at the discretion of the treating physician.
According to local guidelines, outpatient treatment for
FUTI consisted of a 10–14 day course of oral antimicro-
bials (first choice ciprofloxacin 500 mg b.i.d.) [12]. In
case of risk factors for quinolone resistance a single dose
of a long-acting parental antimicrobial, e.g. ceftriaxone
or an aminoglycoside, at the initiation of therapy was ad-
vised while culture results were pending [13].
Admitted patients started with empirical antimicro-
bials intravenously according to local policy and were
switched to an oral antibiotic based on antimicrobial
sensitivity testing of the uropathogen cultured.
Study procedures
Within 24–48 h of notification, qualified research nurses
collected demographic and clinical data by reviewing the
medical record completed with an interview by telephone
or in person, using a standardized questionnaire. A
midstream-catch urine culture and a set of blood cultures
were taken before commencement of antimicrobial ther-
apy. All patients were contacted in person 3–4 days and
28–32 days after enrollment, and contacted by phone at
day 13–15 and day 84–92, to assess clinical outcome.
Urine culture was repeated at the 28–32 day follow-up
visit. In case of (re) admission during the study period, re-
lated data were obtained from the medical record and
interview. In case a patient was lost to follow up, survival
and readmission were assessed by inquiry with the pa-
tient’s primary care physicians, hospital chart and/or local
governmental mortality registries.
Urine and blood cultures were performed using stand-
ard microbiological methods at local certified laborator-
ies. Data collection of patients included during the
validation period was identical (see Additional file 1).
Endpoints
The primary endpoints were primary hospital admission
rate (the percentage of patients who were directly admitted
to hospital) and secondary hospital admission rate (the per-
centage of patients who needed to be hospitalized for FUTI
after initial home-based treatment). Secondary outcome
measures were 30- and 90-day all-cause mortality rate, ICU
admission rate, the total number of hospitalization days
over a 3-month follow-up and clinical- and microbiological
cure rate through the 10- to 18-day post-treatment visit.
Clinical cure was defined as being alive with absence of
fever and resolution of UTI symptoms (either absence of
symptoms or at least 2 points improvement on a 0 through
5 points severity score), without additional antimicrobial
therapy for relapse of UTI [14]. Bacteriologic cure was de-
fined as eradication of the study entry uropathogen with no
recurrence of bacteriuria (pathogen growth <104 cfu/mL in
women or <103 cfu/mL in men combined with disappear-
ance of leucocyturia) [15].
A Data Safety Monitoring Board (DSMB) monitored the
study and prescheduled interim analyses were performed
according to predefined stopping rules. For the analysis of
secondary hospital admission only low risk patients
PRACTICE-score = < 100 points were considered.
Definitions
UTI in men, postmenopausal women and in women with
any structural or functional abnormality of the urinary
tract were considered ‘complicated’ whereas in all others it
was considered ‘uncomplicated’ UTI [13, 15]. Comorbidity
was defined as the presence of any urinary tract disorder,
heart failure, cerebrovascular disease, renal insufficiency,
diabetes mellitus, malignancy or chronic obstructive pul-
monary disease.
Statistical analysis
The primary endpoints were analyzed on the intention-
to-treat (ITT) and per-protocol (PP) population.
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Evaluable patients for ITT analysis included all patients
who met the inclusion criteria and had at least 1 follow
up visit. The PP population consisted of cases in which
PRACTICE-hospitalization recommendations were
actually followed in the intervention period and all cases
in the control period. Binomial or categorical outcome
measures were analyzed using Chi-square tests (Pear-
son’s or Fisher’s). Risk difference with 95% confidence
interval (CI) was used to compare the differences of cat-
egorical outcomes. Tests of significance were at 0.05
level, two-tailed, for primary hospital admission rate.
A study sample size of 326 patients in both arms was
calculated on the basis of secondary hospital admission
rate, which was estimated to be approximately 5%, based
on our previous study on FUTI [16], to have a power of
90% to show that the secondary admission rate in the
intervention period (PRACTICE-guided management) is
at least as low as the control period. As we were only in-
terested for non-inferiority and not in equivalence in
secondary hospital admission rate, the sample size calcu-
lation was based on a one-tailed alpha of 0.025. This
implies that the 90% CI of a two-tailed Chi-square test
should not cross the predefined risk difference of 2.5%
higher secondary admission rates. All analyses were per-
formed using SPSS 20.0 (SPPS Inc., USA).
Results
Study participants
A total of 370 patients was included, 237 in the con-
trol period and 133 in the intervention period (see
the flowchart in Fig. 1). In the ITT-population, base-
line demographic characteristics were similar in the
two groups (Table 2), except for a difference in his-
tory of cerebrovascular and chronic renal disease. Pa-
tients in who PRACTICE recommendations were
followed (the PP-analysis) were significantly older, had
more comorbidity and more often suffered compli-
cated UTI than control patients (Table 2).
Fifteen patients who were included in the study by
ED-physicians did not completely meet the predefined
inclusion criteria, but discharge diagnosis as con-
cluded by the attending physician was FUTI in all
Fig. 1 Patient inclusion flow chart
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cases. On hospital presentation, ten of these patients
had no specific symptoms of UTI, 8 of these 10 pa-
tients had cultures of blood (3) and/or urine (5) posi-
tive with significant growth of an uropathogen, 2 had
negative urine cultures, and 1 of them used antibi-
otics at inclusion. The other 5 patients did not have
or report fever at inclusion, 1 of them was on TNFα-
inhibitors.
Follow up was not completed in 37 patients in the con-
trol group and in 13 patients in the intervention group.
Based on review of medical charts and governmental re-
cords these patients were all alive and without secondary
admission, and included as such in the analysis.
Cultures
The results of urine cultures, performed in 347 (93%) pa-
tients are shown in Table 3; 125 (36%) urine cultures were
either sterile or contaminated of which 65% were obtained
during antibiotic (pre)treatment. Blood cultures, performed
in 357 (96%) patients, revealed bacteremia in 97 (27%) cases
(Table 3). Rate of bacteremia was similar in intervention
and control group.
Outcome
The mean PRACTICE scores in the control and inter-
vention groups (ITT analysis) were 62 (95% CI: 57.7 to
65.4) and 64 (95% CI: 58.3 to 69.7), respectively. Mean
PRACTICE score in the PP population was 76 (95% CI:
69.0 to 83.3; p < 0,01).
Use of the PRACTICE significantly reduced primary
hospitalization rate, 96 (72%) patients in the interven-
tion group were admitted in the hospital versus 219
(92%) in the control period (p < 0.01) (Table 4). The
hospitalization rate was further reduced to 57% in the
PP population.
The attending physician overruled the PRACTICE rule
in 50 out of 153 patients categorized as low risk, who were
admitted to the hospital because of ‘sick appearance’
(n = 9), severe flank pain (n = 2), antibiotic treatment at
presentation (n = 7), comorbidity (n = 5), nausea (n = 3),
uncertain diagnosis (n = 4), unknown (n = 7) or other rea-
sons (n = 13). On the other hand, two patients categorized
as high risk were treated at home because they insisted on
home based treatment.
The median number of hospitalization days over a 3-
month follow-up was 5 days (95% CI 5.6 to 7.0) vs 4 days
(95% CI 4.4 to 6.7) for the control and intervention
period, respectively.
Clinical and microbiological cure on day 30 did not
differ significantly between both groups (Table 4).
The clinical outcomes according to risk class are out-
lined in Table 5.
Table 2 Patients’ demographics
Control group Intervention group p
ITT = PP ITT PP Control vs ITT Control vs PP
n = 237 n = 133 n = 81
Age in years; median, (IQR) 60 (30) 61 (34) 71 (26) ns <0,01
Sex – female 148 (62) 74 (56) 33 (41) ns <0,01
Febrile uncomplicated UTI 54 (23) 30 (23) 9 (11) ns 0,02
Antimicrobial treatment at inclusion 90 (38)a 44 (33) 22 (27) ns ns
Urologic history
Present urinary catheter 17 (7) 9 (7) 8 (10) ns ns
History of urinary tract disordera 73 (31) 33 (25) 29 (36) ns ns
Recurrent UTIb 30 (13)c 11 (9)c 5 (7) ns ns
Comorbidity
Any 124 (52) 77 (58) 57 (70) ns <0,01
Diabetes mellitus 36 (15) 29 (22) 25 (31) ns <0,01
Malignancy 13 (5) 11 (8) 10 (12) ns ns
Heart failure 32 (13) 12 (9) 11 (14) ns ns
Cerebrovascular disease 17 (7) 20 (15) 18 (22) 0.02 <0,01
Cirrhosis 1 (0) 2 (1) 1 (1) ns ns
Renal insufficiency 12 (5) 20 (15) 18 (22) <0.01 <0,01
Immunocompromised 19 (8) 10 (8) 5 (6) ns ns
Data are presented as n (%) unless otherwise stated. ITT intention to treat analysis, PP per protocol analysis, IQR interquartile range, ns not significant (at 0,05
level), UTI urinary tract infection. aUrinary tract disorder: presence of any functional or anatomical abnormality of the urinary tract excluding the presence of a
urinary catheter. bRecurrent UTI: two or more episodes in the last 6 months or three or more episodes of UTI in the last year. cUTI history was unknown in 13
subjects in control period and 6 subjects in intervention period
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Safety
In the control period, 18 patients were treated at home
(1 high risk and 17 low risk patients), of which 1 low risk
patient was admitted 5 days after start of home treat-
ment because of flank pain shown to be due to renal
vein thrombosis.
Of the 37 patients in the intervention group who re-
ceived initial home-based treatment (29 low risk, 6 inter-
mediate risk and 2 high risk patients), 10 patients (27%)
had a secondary hospital admission. These 10 patients (7
females; median age 61, range 18–85 years) had a low or
intermediate risk for adverse events according to the
PRACTICE-score (6 low, 4 intermediate), and were
treated with oral ciprofloxacin (n = 9) or amoxicillin-
clavulanic-acid (n = 1). Four out of 10 patients consulted
the ED for re-evaluation on their own initiative because of
worsening of symptoms such as fever or nausea. Six pa-
tients (60%) were contacted by phone by the treating
physician to return to the hospital because of positive re-
sults of blood cultures, which grew Escherichia coli (n = 2,
both ciprofloxacin sensitive), Salmonella paratyphi
(n = 1), Staphylococcus aureus (n = 1) and Streptococcus
Lancefield group A (n = 1) and G (n = 1). Median hospital
stay was 2 days (range 1–14 days). In none of these sec-
ondary admissions intensive care treatment was required,
and no complications were noted.
The first interim analysis, that took place after inclusion
of 133 patients in the intervention group, showed an abso-
lute risk difference in secondary hospital admission rate
between intervention and control cohort of 23% (10/35
(29%) subjects in the intervention cohort, vs 1/17 (6%) in
the control group). Because the difference in secondary
admission rate exceeded the predefined stopping criterion
of 20%, the DSMB advised to stop the trial.
Discussion
We assessed the clinical use of a prediction rule, the PRAC-
TICE, that stratifies patients presenting with FUTI into
three risk groups for short-term mortality or admission to
the ICU, and is based on bed-side available patient charac-
teristics. Our hypothesis that the use of this prediction rule
would reduce hospitalization rate was confirmed in this
study, as shown by a 20% absolute reduction. The impact
of the PRACTICE on admission policy could have been
bigger, because in 33% of low risk patients PRACTICE-
recommendations were overruled by the attending phys-
ician, possibly because of unfamiliarity with the decision
rule. Patients in the PP population were older, had more co-
morbidity and thus a higher PRACTICE score, reflecting
the fact that physicians were more likely to follow PRAC-
TICE guidance when admission was recommended. The
secondary admission rate of 29% exceeded the predefined
stopping criterion (of a 20% absolute increase over that in
the control group), and the study was stopped accordingly.
This real world study underlines the importance of the
validation of clinical prediction rules in a new cohort to
ensure its predictive value and usefulness in clinical set-
ting, but there are some limitations.
The PRACTICE was adapted from the Pneumonia Se-
verity Index (PSI). Selecting candidate predictors for prog-
nostic modelling is generally done by logistic regression
analysis. In order to have sufficient power, as a rule of
thumb, we need at least ten outcomes per candidate pre-
dictor [17]. Predicting 30-day mortality rate of FUTI,
which was estimated to be 2–5%, and considering analysis
of 20 candidate predictors this implies a sample size of at
least 4000–10,000 patients to obtain sufficient power.
Based on previous studies, we realized such a large pro-
spective study would be infeasible. Since the PRACTICE
score was validated in a prospectively collected broad
population of 787 patients and its impact was subse-
quently analyzed in a randomized intervention trial, our
study was conducted according to guidelines for develop-
ment of clinical prediction rules [18, 19]. As the PRAC-
TICE predicts the composite outcome of complicated
Table 3 Bacteria isolated from baseline cultures
Control period Intervention period
n = 237 n = 133
Urine cultures
Escherichia coli 126 (56) 51 (42)
Klebsiella spp 12 (5) 7 (6)
Proteus spp 5 (2) 3 (2)
Enterococcus spp 3 (1) -
Pseudomonas aeruginosa - 1 (1)
Staphylococcus aureus 1 (0) 1 (1)
Other 7 (3) 6 (5)
Contaminated / mixed flora 26 (12) 24 (20)
Total positive urine cultures 154/225 (68)a 69/122 (57)a
Blood cultures
Escherichia coli 56 (25) 21 (68)
Klebsiella spp 4 (6) 4 (13)
Proteus spp - 1 (3)
Enterobacter spp 1 (1) -
Pseudomonas aeruginosa 1 (1) -
Staphylococcus aureus 1 (1) 2 (6)
Beta haemolytic streptococcus 1 (1) 2 (6)
Citrobacter spp 1 (1) -
Bacteroides fragilis 1 (1) -
Salmonella paratyphi - 1 (3)
Total positive blood cultures 66/228 (29)b 31/129 (24)b
Data are presented as n (%). aUrine cultures were not performed in 12 patients
in the control period and 11 patients in the intervention period. bBlood
cultures were not obtained in 9 patients in the control period and 4 patients
in the intervention period
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course (30-day mortality, ICU-admission and prolonged
hospitalisation), according to the rule of thumb (one pre-
dictor for 10 or more outcomes), the validation cohort has
sufficient power for reliable statistical analyses [17].
The trial was stopped because of safety concerns, since
secondary hospital admission reached our predefined stop-
ping rule. We note that all secondary admitted patients
were discharged after a short and uncomplicated hospital
stay. Two readmissions because of E coli bacteremia might
have been avoided, because ciprofloxacin has been shown
to be equally effective orally as intravenously in bacteremic
UTI [20]. Among secondary admissions were patients with
primary bacteremia caused by salmonella, staphylococci
and streptococci, in whom presenting aspecific symptoms,
e.g. fever and back pain, were mistaken for pyelonephritis,
and sent home. Apparently, these patients were ‘misdiag-
nosed’ at first consultation as having FUTI, and subse-
quently were treated for other diagnoses at secondary
admission. We included these patients in our analysis be-
cause the attending physicians at the EDs enrolled the
Table 4 Patients’ outcomes
Control period Intervention period ITT Intervention period PP
n = 237 n = 133 n = 81
Hospitalization
Primary hospitalization 219 (92)* 96 (72)* 46 (57)*
Low risk 136 50 0
Intermediate risk 58 29 29
High risk 25 17 17
Secondary admission (all risk classes) 2/18 (11) 10/37 (27) 10/35 (29)
Low risk 1/17 6/29 6/29
Intermediate risk 0/0 4/6 4/6
High risk 1/1 0/2 0/0
Need for ICU admission 8 (3) 1 (1) 1 (1)
Hospital admission >10 days 15 (6) 10 (8) 9 (11)
Total number of hospitalization days in 90 days of follow up [median, CI] 5 [5,6–7,0] 4 [4,4–6,7] 4 [4,2–7,6]
Bacteremia 66/228 (29) 31/129 (24) 21/77 (27)
Mortality
30-day all-cause mortality 3 (1) 3 (2) 2 (2)
90-day all-cause mortality 7 (3) 5 (4) 4 (5)
Cure at day 30
Clinical cure 182/209 (87) 98/121 (80) 59/73 (81)
Microbiological cure 170/190 (89) 107/113 (95) 61/65 (94)
Data are presented as n (%) unless otherwise stated. CI confidence interval, ITT intention to treat analysis, PP per protocol analysis, ICU intensive care
unit. *p = < 0.001
Table 5 Clinical outcome of febrile urinary tract infection according to PRACTICE risk class; control and intervention groups
combined
PRACTICE score (points) Low risk Intermediate risk High risk Total
Class I-II Class III Class IV-V
(<75) (76–100) (>100)
Control Intervention All Control Intervention All Control Intervention All
No. of patients 153 79 232 58 35 93 26 19 45 370
Clinical outcome
30-day mortality, % 0 0 0 3 (5) 1 (3) 4 (4) 3 (11) 2 (10) 5 (11) 9 (2)
90-day mortality, % 0 0 0 3 (5) 3 (9) 6 (6) 4 (15) 2 (10) 6 (13) 12 (3)
ICU admission, % 3 (2) 0 3 (1) 2 (3) 0 2 (2) 3 (11) 1 (5) 4 (9) 9 (2)
Length of hospital stay
Median no. of days [IQR] 4.0 [2] 3.0 [4] 4.0 [3] 6.0 [4] 4.0 [4] 5.0 [4] 6.5 [4] 6.0 [6] 6.0 [4] 5.0 [3]
Data are presented as n (%) unless otherwise stated, IQR interquartile range, ICU intensive care unit
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patients in the current trial on a presumptive diagnosis of
FUTI and we believe that these diagnostic errors reflect
every day patient care [21].
Acute pyelonephritis and urosepsis are common condi-
tions seen in the ED, and it is of importance to be aware
that other unusual diseases can mimic its general symp-
toms. Other studies support our observation that the accur-
acy of UTI diagnosis may be suboptimal in the ED [22, 23].
Apparently the diagnosis of FUTI is not as straightfor-
ward as the diagnosis of pneumonia, where the presence
of an infiltrate on chest X-ray is both definitive and con-
firmative and clinical decision rules such as the PSI have
been implemented successfully in daily practice [3]. The
PSI was derived from a large cohort of >14,000 patients
and validated in almost 40,000 patients, and studies pro-
spectively addressing its use in clinical practice found sec-
ondary admission rates of 4–9% [24–27]. The fact that we
found higher secondary admission rates in FUTI, might
also be explained by a different pathway leading to failure
of home treatment in these two infections. Whereas re-
spiratory distress is probably the main cause of secondary
hospitalization of pneumonia patients; unability to take
oral medication and need for volume resuscitation is more
important for FUTI patients. These factors might be un-
derrepresented in the composite outcome of complicated
course of FUTI as predicted by the PRACTICE.
Differences in validation and intervention trial cohorts
in this study might have attributed to the difference in sec-
ondary admission rate. In the historical cohort patients
were recruited not only in EDs, but (a minority) also in
the practice of general practitioners. The main difference
with the historical cohort is the higher percentage of com-
plicated UTI (or in some cases, an alternative diagnosis
made on basis of blood culture findings) in the current co-
hort, which cannot be explained by a difference in sex or
age. Other demographic parameters and outcome such as
ICU admissions and mortality were comparable in the his-
torical and current cohort.
Our patient group reflects the daily practice of patients
presenting with community acquired FUTI, as both men
and women, and patients with comorbidity were in-
cluded. A previous study on women with acute pyelo-
nephritis identified factors associated with hospital
admission using a risk stratification model [28].
Age > 65 years, chills, segmented neutrophils >90%, cre-
atinine >1.5 mg/dL, CRP >10 mg/dL and albumin 3.3 g/
dL were independent risk factors for patient admission.
Since details on mortality or complications are not
given, no conclusion can be made on the actual risk for
poor outcome. Furthermore, this model was not vali-
dated in a prospective cohort. In contrast, our PSI de-
rived predictor variables can be readily assessed at the
bedside level on the basis of history and physical
examination.
How can the prediction rule for admission policy be op-
timized? The cut-off value of 75 points had a negative pre-
dictive value for predicting 30-day mortality of 100% in
the intervention cohort. Lowering the threshold for ad-
mission policy in the intervention phase would hypothe-
ticly have led to a hospitalization rate of 77% (102/133),
but would still have resulted in a secondary hospitalization
rate of 19% (6/31). The effect of the acute host response
might be underrepresented in the PRACTICE, because it
is based on the 30-day mortality in the validation cohort.
Prognosis of the patient presenting with severe febrile ill-
ness consist of two factors. Firstly, the severity of the acute
host response to the infection and inflammatory cascade
eventually leading to shock and multi organ failure is best
reflected by the hyperacute mortality. Secondly, the pa-
tients general health condition, mainly defined by age and
comorbidity, that determines the 30-day mortality in pa-
tients who survive the first days of illness. Addition of a
plasma biomarker reflecting the severity of sepsis, such as
procalcitonin or midregional pro-adrenomedullin [29],
might improve the decision rule in identifying patients
who benefit from hospital-based treatment in the acute
phase and lower the secondary admission rate. Further-
more, improved diagnosis of UTI is necessary to ensure
safe implementation of prediction tools regarding clinical
decision making.
Conclusion
Implementation of the PRACTICE rule could decrease
the number of hospital admissions of patients presenting
to the ED with febrile urinary tract infection by 20%, at
the expense of a high secondary admission rate.
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